Skip to contentC
Capricor Therapeutics, Inc.
C
CAPRCapricor Therapeutics, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$40.73M-$40.73MN/M vs Q2 2025 EPS Diluted-$0.70-$0.70N/M vs Q2 2025 Operating Income-$42,945,620N/M Operating Cash Flowderived-$31,485,187N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Capricor Therapeutics, Inc. · CIK 1133869 · Engraved from SEC EDGAR
Free Cash Flowderived-$35,548,122N/M ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end